Nurtec ODT (Rimegepant): The 2034-2039 Generic Opportunity Window

Pfizer's calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec ODT (rimegepant, FDA NDA 212728, 75 mg orally disintegrating tablet) generated $1.26B in 2024 and $1.42B in 2025 across acute migraine and episodic migraine prevention. Core composition-of-matter patent US 8,314,117 carries an extended Patent Term Extension (PTE) expiry of February 27, 2034 (~7.4 years in the future relative to October 2026). Secondary fast-dissolving oral lyophilizate formulation patents (US 11,083,724) extend Orange Book protection through September 16, 2039. Commercial status: 100% Brand-only in the United States today with zero generic rimegepant sold. Indian generic manufacturer Natco Pharma is actively positioned as a first-to-file Paragraph IV ANDA challenger in the U.S. District Court for the District of Delaware targeting 180-day market exclusivity. Scope note: Unresolved litigation claims and confidential settlement discussions are excluded from this analysis.